LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Suletud

Sektor Tervishoid

2.25 -2.17

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.25

Max

2.28

Põhinäitajad
By Trading Economics
Müük	16M 72M
Aktsiakasum	0.26
Töötajad	185

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+88.26 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024

Turustatistika
By TradingEconomics
Turukapital	13M 281M
Eelmine avamishind	4.42
Eelmine sulgemishind	2.25

Uudiste sentiment

By Acuity

50%

94 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

2.25 / 2.45 Toetus ja vastupanu

Puma Biotechnology Inc Graafik

Seotud uudised

21. sept 2023, 20:47 UTC

Suurimad hinnamuutused turgudel

Puma Biotechnology Stock Up 6.9% on New FDA Orphan Drug Designation

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

88.26% tõus

12 kuu keskmine prognoos

Keskmine 4.33 USD 88.26%

Kõrge 7 USD

Madal 2 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.25 / 2.45Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

94 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI), that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment for patients with HER2-positive metastatic breast cancer. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors. The Company has two subsidiaries: Puma Biotechnology Ltd and Puma Biotechnology, B.V.